Waveform optimization for internal cardioversion of atrial fibrillation
Abstract Introduction A novel atrial defibrillator was developed at the Royal Victoria Hospital in collaboration with the Nanotechnology and Integrated Bio-Engineering Centre, University of Ulster. This device is powered by an external pulse of radiofrequency energy and designed to cardiovert using...
Gespeichert in:
Veröffentlicht in: | Journal of electrocardiology 2011-11, Vol.44 (6), p.689-693 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 693 |
---|---|
container_issue | 6 |
container_start_page | 689 |
container_title | Journal of electrocardiology |
container_volume | 44 |
creator | Kodoth, Vivek, MBBS, MRCP (UK) Castro, Noel C., BSc, MSc Glover, Ben M., MB BCh, MD, MRCP (UK) Anderson, Jim M., BSc, MPhil, PhD Escalona, Omar J., BSc, MSC, PhD Lau, Ernest, MB BCh, MD, MRCP (UK) Manoharan, Ganesh, MB BCh, MD, FRCP (UK) |
description | Abstract Introduction A novel atrial defibrillator was developed at the Royal Victoria Hospital in collaboration with the Nanotechnology and Integrated Bio-Engineering Centre, University of Ulster. This device is powered by an external pulse of radiofrequency energy and designed to cardiovert using low-tilt monophasic waveform (LTMW) and low-tilt biphasic waveform (LTBW), 12 milliseconds pulse width. This study compared the safety and efficacy of LTMW with LTBW for transvenous cardioversion of atrial fibrillation (AF). Methods Patients were anticoagulated with warfarin to maintain International Normalized Ratio between 2 and 3 for 4 weeks prior cardioversion. Warfarin international normalized ratio level was maintained in between 2 and 3 for 4 weeks prior cardioversion. St Jude's defibrillating catheter was positioned in the distal coronary sinus and right atrium and connected to the defibrillator via a junction box. After a test shock using a dummy load, the patient was cardioverted in a step-up progression from 50 to 300 V. Shock success was defined as return of sinus rhythm for 30 seconds or more. If cardioversion was unsuccessful at peak voltage, the patient was crossed over to the other arm of the waveform type and cardioverted at peak voltage. Results Thirty patients were randomized equally to LTBW and LTMW (15 each). Seven out of 15 patients (46%) cardioverted to sinus rhythm with LTBW, and 1 (6%) of 15, with LTMW ( P = .035). Including crossover patients, 14 patients (46%) converted to sinus rhythm. After crossover, 4 patients were cardioverted with LTBW and 2 with LTMW. Overall mean voltage, current, and energy used for cardioversion were 270.53 ± 35.96 V, 3.68 ± 0.80 A, and 9.12 ± 3.73 J, respectively, and intracardiac impedance was 70.82 ± 13.46 Ω. For patients who were successfully cardioverted, mean voltage, current, energy, and intracardiac impedance were 268.28 ± 42.41 V, 3.52 ± 0.63 A, 8.51 ± 3.16 J, and 73.92 ± 12.01 Ω. There were no major adverse complications during the study. Cardiac markers measured postcardioversion were unremarkable. Conclusion Low-tilt biphasic waveform was more efficacious for low-energy transvenous cardioversion of AF. A significant proportion of patients were successfully cardioverted to sinus rhythm with low energy. Radiofrequency-powered defibrillation can be safely used for transvenous cardioversion of AF. |
doi_str_mv | 10.1016/j.jelectrocard.2011.08.008 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_900636241</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022073611003104</els_id><sourcerecordid>900636241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-db9b0a83861f836cee6a707f33dd1007506c0eda6d731d880864443a8920a1063</originalsourceid><addsrcrecordid>eNqNkc1q3DAUhUVpaCaTvkIw3XRl5-onsqaLQpkmk0AgiyR0KTTSNcixrankGUifPnJmWkpWWQmuzjlX-g4hXyhUFKg8b6sWO7RjDNZEVzGgtAJVAagPZEYvOCuV4PCRzAAYK6Hm8picpNQCwILV7BM5ZtmjhBIzsvpldtiE2BdhM_re_zGjD0ORJ4UfRoyD6Yppiw87jGm6Ck1hxujzvPHr6Lvu1XFKjhrTJfx8OOfk8eryYXld3t6tbpY_bksruBhLt16swSiuJG0UlxZRmhrqhnPnKEB9AdICOiNdzalTCpQUQnCjFgwMBcnn5Os-dxPD7y2mUfc-WcyvGDBsk15AFkkmaFZ-2yttDClFbPQm-t7EZ01BTxx1q__nqCeOGpTOHLP57LBmu-7R_bP-BZcFP_cCzJ_deYw6WY-DRedjjtQu-Pft-f4mxnZ-8NZ0T_iMqQ3bqYGkqU5Mg76fGp0KpRkWpyD4CzVsn8g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>900636241</pqid></control><display><type>article</type><title>Waveform optimization for internal cardioversion of atrial fibrillation</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Kodoth, Vivek, MBBS, MRCP (UK) ; Castro, Noel C., BSc, MSc ; Glover, Ben M., MB BCh, MD, MRCP (UK) ; Anderson, Jim M., BSc, MPhil, PhD ; Escalona, Omar J., BSc, MSC, PhD ; Lau, Ernest, MB BCh, MD, MRCP (UK) ; Manoharan, Ganesh, MB BCh, MD, FRCP (UK)</creator><creatorcontrib>Kodoth, Vivek, MBBS, MRCP (UK) ; Castro, Noel C., BSc, MSc ; Glover, Ben M., MB BCh, MD, MRCP (UK) ; Anderson, Jim M., BSc, MPhil, PhD ; Escalona, Omar J., BSc, MSC, PhD ; Lau, Ernest, MB BCh, MD, MRCP (UK) ; Manoharan, Ganesh, MB BCh, MD, FRCP (UK)</creatorcontrib><description>Abstract Introduction A novel atrial defibrillator was developed at the Royal Victoria Hospital in collaboration with the Nanotechnology and Integrated Bio-Engineering Centre, University of Ulster. This device is powered by an external pulse of radiofrequency energy and designed to cardiovert using low-tilt monophasic waveform (LTMW) and low-tilt biphasic waveform (LTBW), 12 milliseconds pulse width. This study compared the safety and efficacy of LTMW with LTBW for transvenous cardioversion of atrial fibrillation (AF). Methods Patients were anticoagulated with warfarin to maintain International Normalized Ratio between 2 and 3 for 4 weeks prior cardioversion. Warfarin international normalized ratio level was maintained in between 2 and 3 for 4 weeks prior cardioversion. St Jude's defibrillating catheter was positioned in the distal coronary sinus and right atrium and connected to the defibrillator via a junction box. After a test shock using a dummy load, the patient was cardioverted in a step-up progression from 50 to 300 V. Shock success was defined as return of sinus rhythm for 30 seconds or more. If cardioversion was unsuccessful at peak voltage, the patient was crossed over to the other arm of the waveform type and cardioverted at peak voltage. Results Thirty patients were randomized equally to LTBW and LTMW (15 each). Seven out of 15 patients (46%) cardioverted to sinus rhythm with LTBW, and 1 (6%) of 15, with LTMW ( P = .035). Including crossover patients, 14 patients (46%) converted to sinus rhythm. After crossover, 4 patients were cardioverted with LTBW and 2 with LTMW. Overall mean voltage, current, and energy used for cardioversion were 270.53 ± 35.96 V, 3.68 ± 0.80 A, and 9.12 ± 3.73 J, respectively, and intracardiac impedance was 70.82 ± 13.46 Ω. For patients who were successfully cardioverted, mean voltage, current, energy, and intracardiac impedance were 268.28 ± 42.41 V, 3.52 ± 0.63 A, 8.51 ± 3.16 J, and 73.92 ± 12.01 Ω. There were no major adverse complications during the study. Cardiac markers measured postcardioversion were unremarkable. Conclusion Low-tilt biphasic waveform was more efficacious for low-energy transvenous cardioversion of AF. A significant proportion of patients were successfully cardioverted to sinus rhythm with low energy. Radiofrequency-powered defibrillation can be safely used for transvenous cardioversion of AF.</description><identifier>ISSN: 0022-0736</identifier><identifier>EISSN: 1532-8430</identifier><identifier>DOI: 10.1016/j.jelectrocard.2011.08.008</identifier><identifier>PMID: 22018484</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Atrial Fibrillation - therapy ; Cardiac Catheterization ; Cardiovascular ; Defibrillators, Implantable ; Electric Countershock - instrumentation ; Electric Countershock - methods ; Humans ; Middle Aged ; Warfarin - administration & dosage</subject><ispartof>Journal of electrocardiology, 2011-11, Vol.44 (6), p.689-693</ispartof><rights>Elsevier Inc.</rights><rights>2011 Elsevier Inc.</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-db9b0a83861f836cee6a707f33dd1007506c0eda6d731d880864443a8920a1063</citedby><cites>FETCH-LOGICAL-c434t-db9b0a83861f836cee6a707f33dd1007506c0eda6d731d880864443a8920a1063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jelectrocard.2011.08.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22018484$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kodoth, Vivek, MBBS, MRCP (UK)</creatorcontrib><creatorcontrib>Castro, Noel C., BSc, MSc</creatorcontrib><creatorcontrib>Glover, Ben M., MB BCh, MD, MRCP (UK)</creatorcontrib><creatorcontrib>Anderson, Jim M., BSc, MPhil, PhD</creatorcontrib><creatorcontrib>Escalona, Omar J., BSc, MSC, PhD</creatorcontrib><creatorcontrib>Lau, Ernest, MB BCh, MD, MRCP (UK)</creatorcontrib><creatorcontrib>Manoharan, Ganesh, MB BCh, MD, FRCP (UK)</creatorcontrib><title>Waveform optimization for internal cardioversion of atrial fibrillation</title><title>Journal of electrocardiology</title><addtitle>J Electrocardiol</addtitle><description>Abstract Introduction A novel atrial defibrillator was developed at the Royal Victoria Hospital in collaboration with the Nanotechnology and Integrated Bio-Engineering Centre, University of Ulster. This device is powered by an external pulse of radiofrequency energy and designed to cardiovert using low-tilt monophasic waveform (LTMW) and low-tilt biphasic waveform (LTBW), 12 milliseconds pulse width. This study compared the safety and efficacy of LTMW with LTBW for transvenous cardioversion of atrial fibrillation (AF). Methods Patients were anticoagulated with warfarin to maintain International Normalized Ratio between 2 and 3 for 4 weeks prior cardioversion. Warfarin international normalized ratio level was maintained in between 2 and 3 for 4 weeks prior cardioversion. St Jude's defibrillating catheter was positioned in the distal coronary sinus and right atrium and connected to the defibrillator via a junction box. After a test shock using a dummy load, the patient was cardioverted in a step-up progression from 50 to 300 V. Shock success was defined as return of sinus rhythm for 30 seconds or more. If cardioversion was unsuccessful at peak voltage, the patient was crossed over to the other arm of the waveform type and cardioverted at peak voltage. Results Thirty patients were randomized equally to LTBW and LTMW (15 each). Seven out of 15 patients (46%) cardioverted to sinus rhythm with LTBW, and 1 (6%) of 15, with LTMW ( P = .035). Including crossover patients, 14 patients (46%) converted to sinus rhythm. After crossover, 4 patients were cardioverted with LTBW and 2 with LTMW. Overall mean voltage, current, and energy used for cardioversion were 270.53 ± 35.96 V, 3.68 ± 0.80 A, and 9.12 ± 3.73 J, respectively, and intracardiac impedance was 70.82 ± 13.46 Ω. For patients who were successfully cardioverted, mean voltage, current, energy, and intracardiac impedance were 268.28 ± 42.41 V, 3.52 ± 0.63 A, 8.51 ± 3.16 J, and 73.92 ± 12.01 Ω. There were no major adverse complications during the study. Cardiac markers measured postcardioversion were unremarkable. Conclusion Low-tilt biphasic waveform was more efficacious for low-energy transvenous cardioversion of AF. A significant proportion of patients were successfully cardioverted to sinus rhythm with low energy. Radiofrequency-powered defibrillation can be safely used for transvenous cardioversion of AF.</description><subject>Aged</subject><subject>Atrial Fibrillation - therapy</subject><subject>Cardiac Catheterization</subject><subject>Cardiovascular</subject><subject>Defibrillators, Implantable</subject><subject>Electric Countershock - instrumentation</subject><subject>Electric Countershock - methods</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Warfarin - administration & dosage</subject><issn>0022-0736</issn><issn>1532-8430</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1q3DAUhUVpaCaTvkIw3XRl5-onsqaLQpkmk0AgiyR0KTTSNcixrankGUifPnJmWkpWWQmuzjlX-g4hXyhUFKg8b6sWO7RjDNZEVzGgtAJVAagPZEYvOCuV4PCRzAAYK6Hm8picpNQCwILV7BM5ZtmjhBIzsvpldtiE2BdhM_re_zGjD0ORJ4UfRoyD6Yppiw87jGm6Ck1hxujzvPHr6Lvu1XFKjhrTJfx8OOfk8eryYXld3t6tbpY_bksruBhLt16swSiuJG0UlxZRmhrqhnPnKEB9AdICOiNdzalTCpQUQnCjFgwMBcnn5Os-dxPD7y2mUfc-WcyvGDBsk15AFkkmaFZ-2yttDClFbPQm-t7EZ01BTxx1q__nqCeOGpTOHLP57LBmu-7R_bP-BZcFP_cCzJ_deYw6WY-DRedjjtQu-Pft-f4mxnZ-8NZ0T_iMqQ3bqYGkqU5Mg76fGp0KpRkWpyD4CzVsn8g</recordid><startdate>20111101</startdate><enddate>20111101</enddate><creator>Kodoth, Vivek, MBBS, MRCP (UK)</creator><creator>Castro, Noel C., BSc, MSc</creator><creator>Glover, Ben M., MB BCh, MD, MRCP (UK)</creator><creator>Anderson, Jim M., BSc, MPhil, PhD</creator><creator>Escalona, Omar J., BSc, MSC, PhD</creator><creator>Lau, Ernest, MB BCh, MD, MRCP (UK)</creator><creator>Manoharan, Ganesh, MB BCh, MD, FRCP (UK)</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20111101</creationdate><title>Waveform optimization for internal cardioversion of atrial fibrillation</title><author>Kodoth, Vivek, MBBS, MRCP (UK) ; Castro, Noel C., BSc, MSc ; Glover, Ben M., MB BCh, MD, MRCP (UK) ; Anderson, Jim M., BSc, MPhil, PhD ; Escalona, Omar J., BSc, MSC, PhD ; Lau, Ernest, MB BCh, MD, MRCP (UK) ; Manoharan, Ganesh, MB BCh, MD, FRCP (UK)</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-db9b0a83861f836cee6a707f33dd1007506c0eda6d731d880864443a8920a1063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Atrial Fibrillation - therapy</topic><topic>Cardiac Catheterization</topic><topic>Cardiovascular</topic><topic>Defibrillators, Implantable</topic><topic>Electric Countershock - instrumentation</topic><topic>Electric Countershock - methods</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Warfarin - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kodoth, Vivek, MBBS, MRCP (UK)</creatorcontrib><creatorcontrib>Castro, Noel C., BSc, MSc</creatorcontrib><creatorcontrib>Glover, Ben M., MB BCh, MD, MRCP (UK)</creatorcontrib><creatorcontrib>Anderson, Jim M., BSc, MPhil, PhD</creatorcontrib><creatorcontrib>Escalona, Omar J., BSc, MSC, PhD</creatorcontrib><creatorcontrib>Lau, Ernest, MB BCh, MD, MRCP (UK)</creatorcontrib><creatorcontrib>Manoharan, Ganesh, MB BCh, MD, FRCP (UK)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of electrocardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kodoth, Vivek, MBBS, MRCP (UK)</au><au>Castro, Noel C., BSc, MSc</au><au>Glover, Ben M., MB BCh, MD, MRCP (UK)</au><au>Anderson, Jim M., BSc, MPhil, PhD</au><au>Escalona, Omar J., BSc, MSC, PhD</au><au>Lau, Ernest, MB BCh, MD, MRCP (UK)</au><au>Manoharan, Ganesh, MB BCh, MD, FRCP (UK)</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Waveform optimization for internal cardioversion of atrial fibrillation</atitle><jtitle>Journal of electrocardiology</jtitle><addtitle>J Electrocardiol</addtitle><date>2011-11-01</date><risdate>2011</risdate><volume>44</volume><issue>6</issue><spage>689</spage><epage>693</epage><pages>689-693</pages><issn>0022-0736</issn><eissn>1532-8430</eissn><abstract>Abstract Introduction A novel atrial defibrillator was developed at the Royal Victoria Hospital in collaboration with the Nanotechnology and Integrated Bio-Engineering Centre, University of Ulster. This device is powered by an external pulse of radiofrequency energy and designed to cardiovert using low-tilt monophasic waveform (LTMW) and low-tilt biphasic waveform (LTBW), 12 milliseconds pulse width. This study compared the safety and efficacy of LTMW with LTBW for transvenous cardioversion of atrial fibrillation (AF). Methods Patients were anticoagulated with warfarin to maintain International Normalized Ratio between 2 and 3 for 4 weeks prior cardioversion. Warfarin international normalized ratio level was maintained in between 2 and 3 for 4 weeks prior cardioversion. St Jude's defibrillating catheter was positioned in the distal coronary sinus and right atrium and connected to the defibrillator via a junction box. After a test shock using a dummy load, the patient was cardioverted in a step-up progression from 50 to 300 V. Shock success was defined as return of sinus rhythm for 30 seconds or more. If cardioversion was unsuccessful at peak voltage, the patient was crossed over to the other arm of the waveform type and cardioverted at peak voltage. Results Thirty patients were randomized equally to LTBW and LTMW (15 each). Seven out of 15 patients (46%) cardioverted to sinus rhythm with LTBW, and 1 (6%) of 15, with LTMW ( P = .035). Including crossover patients, 14 patients (46%) converted to sinus rhythm. After crossover, 4 patients were cardioverted with LTBW and 2 with LTMW. Overall mean voltage, current, and energy used for cardioversion were 270.53 ± 35.96 V, 3.68 ± 0.80 A, and 9.12 ± 3.73 J, respectively, and intracardiac impedance was 70.82 ± 13.46 Ω. For patients who were successfully cardioverted, mean voltage, current, energy, and intracardiac impedance were 268.28 ± 42.41 V, 3.52 ± 0.63 A, 8.51 ± 3.16 J, and 73.92 ± 12.01 Ω. There were no major adverse complications during the study. Cardiac markers measured postcardioversion were unremarkable. Conclusion Low-tilt biphasic waveform was more efficacious for low-energy transvenous cardioversion of AF. A significant proportion of patients were successfully cardioverted to sinus rhythm with low energy. Radiofrequency-powered defibrillation can be safely used for transvenous cardioversion of AF.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>22018484</pmid><doi>10.1016/j.jelectrocard.2011.08.008</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-0736 |
ispartof | Journal of electrocardiology, 2011-11, Vol.44 (6), p.689-693 |
issn | 0022-0736 1532-8430 |
language | eng |
recordid | cdi_proquest_miscellaneous_900636241 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Aged Atrial Fibrillation - therapy Cardiac Catheterization Cardiovascular Defibrillators, Implantable Electric Countershock - instrumentation Electric Countershock - methods Humans Middle Aged Warfarin - administration & dosage |
title | Waveform optimization for internal cardioversion of atrial fibrillation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A13%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Waveform%20optimization%20for%20internal%20cardioversion%20of%20atrial%20fibrillation&rft.jtitle=Journal%20of%20electrocardiology&rft.au=Kodoth,%20Vivek,%20MBBS,%20MRCP%20(UK)&rft.date=2011-11-01&rft.volume=44&rft.issue=6&rft.spage=689&rft.epage=693&rft.pages=689-693&rft.issn=0022-0736&rft.eissn=1532-8430&rft_id=info:doi/10.1016/j.jelectrocard.2011.08.008&rft_dat=%3Cproquest_cross%3E900636241%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=900636241&rft_id=info:pmid/22018484&rft_els_id=S0022073611003104&rfr_iscdi=true |